MONTREAL, May 28, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. ("HPQ" or the "Company") (TSX- V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to inform shareholders that the leading global fumed silica manufacturer—under the LOI announced on July 9, 2024—has requested to receive samples of the material earlier than initially scheduled. This follows HPQ's May 21, 2025, press release confirming the independent validation ...

Core Viewpoint - Keros Therapeutics emphasizes the importance of its board in overseeing the strategic review process and urges stockholders to support its director nominees to maximize company value amid challenges posed by ADAR1's campaign [1][2][3]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [10][11]. - The company is advancing several product candidates, including cibotercept for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept for cytopenias [10][11]. Board Composition and Strategy - The Keros Board consists of nine independent directors, including four stockholder representatives, bringing diverse expertise in biotechnology, drug development, and capital allocation [7]. - The board is currently engaged in a strategic alternatives review process, which is seen as a constructive step to address shareholder concerns and maximize value [3][8]. Proxy Advisory Firm Recommendations - Glass Lewis & Co. has recommended that Keros stockholders vote "FOR" all three of the company's director nominees, recognizing their qualifications and the board's efforts to enhance stockholder value [1][3]. - The board's decision to retain flexibility through a formal strategic review is viewed as a reasonable approach, contrasting with ADAR1's aggressive campaign [3][5]. Response to ADAR1's Campaign - Keros has responded to claims made by ADAR1, stating that the recent share price decline is primarily due to clinical development risks rather than board mismanagement [3][4]. - The company argues that ADAR1 has not provided compelling evidence against the board members and that the board's actions have been in the best interests of all stockholders [3][6].

Core Viewpoint - ESGold Corp. has successfully delivered its Humphrey spiral concentrators to the Montauban site, marking a significant milestone in its construction timeline as it advances toward production of gold, silver, and mica from historic tailings [1][8]. Company Progress - The gravity separation circuit is designed to process up to 1,000 tonnes per day (TPD) of tailings, converting them into a marketable mica concentrate while also recovering gold and silver [2][6]. - The installation of the gravity separation system is a foundational step for ESGold, positioning the company to become one of Canada's next gold and silver mining entities [5][9]. - The Humphrey Spirals are recognized for their efficiency and low operating costs, operating without chemical reagents, making them suitable for high-throughput tailings reprocessing [6][7]. Future Outlook - ESGold is focused on disciplined execution and operational readiness, with an updated Preliminary Economic Assessment (PEA) expected to outline enhanced project economics based on current metal prices [8][12]. - The company remains on track for first production by the end of 2025, with ongoing construction and key infrastructure in place [12].

Core Viewpoint - UroGen Pharma Ltd. has been downgraded from Buy to Neutral by HC Wainwright & Co. analyst Raghuram Selvaraju due to the FDA's Oncologic Drugs Advisory Committee voting 5-4 against the benefit-risk profile of its investigational therapy UGN-102 for bladder cancer [1][2]. Financial Position - UroGen concluded Q1 2025 with approximately $200 million in cash, cash equivalents, and marketable securities, which is expected to sustain operations through late 2026 even if UGN-102 fails to secure regulatory approval [4]. - The analyst forecasts a net loss of $2.14 per share for 2026, a significant change from the previous projection of earnings of 27 cents [4]. Development Pipeline - UroGen is advancing the development of UGN-103 and UGN-104, next-generation mitomycin-based formulations, which utilize the RTGel delivery platform combined with a novel mitomycin formulation licensed from medac GmbH [5]. - The Phase 3 UTOPIA trial for UGN-103 is currently enrolling patients, with enrollment expected to conclude by mid-2025 and top-line data anticipated shortly thereafter [5][6]. - If the results from UGN-103 are positive, a regulatory submission could occur in 2026, potentially leading to FDA approval by 2027 [6].

BASF SE (BASFY) announced a strategic shift in its copper hydrometallurgy business by intensifying the efforts to develop the next generation of leaching aids with enhanced efficiency. Additionally, the LixTRA product line will also be further advanced to drive innovative solutions. The shift is in response to the ever-increasing demand for copper and the industry’s need for sustainable and resource-efficient processing.To enable this shift, BASF will be relocating its Global R&D leaching activities from Tu ...

Summary of Technova Conference Call Company Overview - **Company**: Technova - **Industry**: Life Sciences, specifically reagents for biotech, pharma, and diagnostics - **Founded**: 1996 by a scientist from Genentech - **Public Offering**: Took the company public in February 2021 Key Points and Arguments - **Market Position**: Technova is a leading provider of reagents for the life science community, serving over 3,000 customers in the U.S. [3][4] - **Growth Trajectory**: The company has historically grown at 12% since February 2009 and aims for a top-line growth of 20-25% due to clinical programs in the pipeline [4][47] - **Revenue Potential**: Technova is positioned to scale its business to $200-250 million in revenue without significant additional capital expenditures (CapEx) [4][41] - **Gross Margin**: 70% of every additional dollar in revenue contributes to the bottom line, indicating strong profitability potential [5][56] - **Customer Retention**: The company boasts a 95% retention rate of its customer base year on year, making it difficult for customers to switch suppliers [53] Product Offerings - **Product Categories**: - Catalog products (60% of business) for general R&D and academic use [16] - Custom products (35% of business), with 25% of that being biopharma-related [18] - **Growth in Custom Products**: Custom biopharma products grew by 40% last year, indicating strong demand [18] - **Speed of Delivery**: Technova can deliver research-use products in 2-3 weeks and custom GMP products in 4-8 weeks, significantly faster than competitors who may take 4-8 months [28][29] Competitive Advantage - **Customization and Quality**: Technova focuses on providing high-quality, customized reagents quickly, which is a gap in the market compared to larger players [10][19] - **Modular Manufacturing**: The company employs a modular manufacturing approach, allowing for flexibility in production sizes and formulations [25][27] - **Customer Service**: High levels of customer service and support, reflected in a net promoter score in the seventies [22] Financial Outlook - **Capital Position**: Technova had $26 million in cash at the end of Q1 and an untapped revolving line of credit, providing a solid financial foundation [61] - **Path to Profitability**: Adjusted EBITDA breakeven is expected at $50-55 million in revenue, with cash flow positive anticipated shortly thereafter [62] Industry Context - **Biotech Environment**: The company is navigating a challenging biotech funding environment but continues to gain clinical customers, projecting a 15% growth in this segment by 2025 [52] - **Regulatory Impact**: Technova feels insulated from tariff impacts due to its U.S.-based manufacturing and limited reliance on foreign raw materials [49][50] Future Strategies - **Partnerships and Collaborations**: Technova is looking to expand partnerships, such as the recent collaboration with Pluristics for cryopreservation media, to enhance its product offerings [45][58] - **Focus on Emerging Therapies**: The company aims to support the growing complexity in bioprocessing for therapies like cell and gene therapy, which require more customized solutions [36][39] Conclusion - **Long-term Growth**: Technova is positioned for sustainable growth with a strong foundational business, significant investments already made, and a clear strategy to scale operations without the need for further major investments [47][48]

Baghouse-collected fumed silica yield is outperforming initial projections at this pilot stage MONTREAL, May 21, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. ("HPQ" or the "Company") (TSX- V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company developing next-generation processes for advanced material manufacturing, is pleased to inform shareholders that it has received an independent analysis confirming fumed silica production. The analysis confirms Fumed Silica was produced by HPQ Silica Polvere Inc. ("HSPI") ...

SENAI CIMATEC, based in Salvador, Bahia, operates as a leading Brazilian hub for technology, innovation, and industrial development. The institution specializes in robotics, advanced manufacturing, aerospace, mineral and mining technologies. SENAI CIMATEC maintains cooperative research agreements with renowned global institutions including MIT, the University of Virginia, and the Fraunhofer Institute. A link to the full announcement can be found here. Contacts SYDNEY, May 20, 2025 (GLOBE NEWSWIRE) -- Brazil ...

Core Insights - Harmonic has expanded its partnership with Cignal TV to modernize channel origination, playout, and disaster recovery workflows using its VOS360 Media SaaS platform, which operates on the public cloud [1][2] - The VOS360 Media SaaS enhances Cignal TV's video streaming and broadcast services by providing greater flexibility, agility, and scalability, allowing for the rapid launch of streaming services [2][4] - The solution enables remote switching of local playout operations to the cloud for disaster recovery, ensuring service continuity and high availability for Cignal TV [3][4] Company Overview - Harmonic is a leader in virtualized broadband and video delivery solutions, enabling media companies and service providers to deliver high-quality video streaming and broadcast services globally [6] - The company has revolutionized broadband networking with the first virtualized broadband solution, allowing operators to deploy gigabit internet services more flexibly [6] - Harmonic's innovative cloud and software platforms simplify OTT video delivery and enhance the monetization of live and on-demand content across various screens [6]

Core Insights - ClassOne Technology has signed a joint development agreement with IBM Research to focus on wet processing for advanced packaging in semiconductor manufacturing [1][2] - The collaboration aims to develop best known methods (BKMs) for non-NMP solvent processing, which is crucial for manufacturing IBM semiconductor devices [2] - ClassOne has been a strategic supplier to IBM since 2014, expanding its technology offerings from electroplating and metal lift-off to advanced packaging applications [3][4] Company Overview - ClassOne Technology is a leading provider of advanced electroplating and wet processing systems for semiconductor and microelectronic device manufacturing globally [4] - The company's flagship Solstice platform offers highly configurable, fully automated wet processing applications with competitive ROI, serving critical wafer processes for various markets including photonics, power, 5G, microLED, and MEMS [4]